Effects of D-003 on the Lipid Profile of Patients with Type II Hypercholesterolaemia: A Phase II Clinical Study

Clinical Drug Investigation

Volumn 23, Issue 12, 2003, Pages 789-802

  Castaño, Gladys ^a   Mas, Rosa ^b   Fernández, Lilia ^b   Illnait, José ^b   López, Ernesto ^a   Gámez, Rafael ^b   Mendoza, Sarahi ^b   Fernández, Julio ^b   Mesa, Meylin ^a  

^a Medical Surgical Research Center   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARACHIDONIC ACID; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; COLLAGEN; CREATINE KINASE; CREATININE; D 003; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ISOLATION; DRUG MEGADOSE; DRUG PURIFICATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PHASE 2 CLINICAL TRIAL; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUGARCANE; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0346101506     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323120-00004     Document Type: Article

References (28)

1. Murray CJL, López AD. Alternate projections of mortality and disability by cause 1990-2020: Global Burden Disease Study. Lancet 1997; 349: 1498-504
2. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II: the relationship of reduction in the incidence of coronary heart disease to cholesterol-lowering. JAMA 1984; 251: 365-74
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
4. Sacks FM, Pfeffer MA, Moyé LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22
6. Shepherd S, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
7. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled study. Lancet 2002; 360: 1623-30
8. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
9. Muls E, De Backer G, De Bacquer D, et al. LIPI-WATCH, a Belgian/Luxembourg survey on achievement of European Atherosclerosis Society lipid goals. Pharmacoepidemiology 2000; 19: 219-29
10. Smith DG, Leslie SJ, Szucs TD, et al. Cost of treating to a modified European Atherosclerosis Society LDL-C target: comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. Clin Drug Invest 1999; 17: 185-93
11. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidemia. Drugs 1997; 53: 828-47
12. Davidson MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidemia. Expert Opin Investig Drugs 2002; 11: 125-41
13. Ose L, Kastelein JJP, Scott R, et al. Efficacy and six-month safety of simvastatin 80 mg/d: results from the Worldwide Simvastatin Expanded Dose Program (WSEDP). Nutr Metab Cardiovasc Dis 1998; 8: 135-43
14. Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001; 24: 258-72
15. González L, Marrero D, Laguna A, et al. A mixture of primary fatty acids obtained from sugar cane wax, PAT CU 35/97. Laboratories Dalmer SA, assignee. Republic of South Africa patent 98-2744, 1998
16. Gámez R, Mendoza S, Más R, et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res 2000; 61: 8-16
17. Castaño G, Mas R, Fernández L, et al. Assessment of the effects of D-003, a new antiplatelet and lipid-lowering compound, in healthy volunteers. Drugs R D 2002; 3: 337-48
18. Castaño G, Menéndez R, Mas R, et al. Effects of D-003 on lipid profile and lipid peroxidation in healthy volunteers. Clin Drug Invest 2003; 23: 193-203
19. Menéndez R, Mas R, Amor AM, et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol Res 2001; 44: 299-304
20. Molina V, Arruzazabala ML, Carbajal D, et al. Antithrombotic effects of D003. Pharmacol Res 2000; 42: 137-43
21. Arruzazabala ML, Carbajal D, Mas R, et al. Effects of D-003, a new compound purified from sugar cane wax, on platelet aggregation in healthy volunteers: a randomized, double-blinded clinical study. Clin Drug Invest 2002; 23: 107-18
22. Gámez R, Mas R, Noa M, et al. Six-month toxicity study of oral administration of D-003 in Sprague Dawley rats. Drugs R D 2002; 3: 375-86
23. Gámez R, Más R, Noa M, et al. Acute and subchronic oral toxicity of D-003 in rats. Toxicol Lett 2000; 118: 31-41
24. Gámez R, Mendoza S, Mas R, et al. Comparison of the cholesterol-lowering effects and toxicity of D-003 and lovastatin on normocholesterolemic rabbits. Drugs R D 2003; 4 (4): 219-29
25. Gámez R, González JE, Rodeiro I, et al. In vivo genotoxic evaluation of D-003, a mixture of very long-chain aliphatic acids. J Med Food 2001; 4: 85-92
26. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197-204
27. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem 1981; 27: 838-41
28. Friedewald WT, Levy RI, Friederickson SD. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502